
Tenet Medicines
About Tenet Medicines
Tenet Medicines is a Healthcare company based in Scotch Plains (United States) founded in 2023, and was acquired by Eliem Therapeutics in April 2024. Therapeutics for autoimmune-driven inflammatory diseases are developed. Its chief executive, as recorded, is Stephen Thomas. Its focus areas include Life Sciences, Immunology, Drugs and Autoimmune Diseases.
Company details
Tenet Medicines was founded in 2023 and is based in Scotch Plains, United States. Focus is placed on the biotechnology sector, where therapeutics for autoimmune-driven inflammatory diseases are developed. The product pipeline includes TNT119, also known as budoprutug, an anti-CD19 monoclonal antibody designed to deplete B-cells. Indications addressed include systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. Operations center on advancing these treatments through clinical development.
- Headquarters Scotch Plains, United States
- Stage Acquired
- SectorsHealthcare
- Acquired by Eliem Therapeutics (Apr 2024)
- Investors
- Acquired byEliem Therapeutics
(Apr 2024)
Investors in Tenet Medicines
Tenet Medicines has secured backing from 1 investor. Prominent investors backing the company include Eliem Therapeutics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Develops antibody-based treatments for autoimmune and inflammatory disorders. | 2018 | eliemtx.com | Boston, United States |
Investor details for Tenet Medicines
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Tenet Medicines
1 people are tracked at Tenet Medicines (1 in leadership).
| Name | Role | Group |
|---|---|---|
Stephen Thomas | CEO | Leadership |
Complete people profiles for Tenet Medicines
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Tenet Medicines
2 dated milestones of Tenet Medicines across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Tenet Medicines is founded.
- Exit Acquired by Eliem Therapeutics.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Tenet Medicines (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Tenet Medicines
Tenet Medicines was founded in 2023.
Tenet Medicines is headquartered in Scotch Plains, United States. It is registered at Scotch Plains, New Jersey, United States.
Stephen Thomas is the CEO of Tenet Medicines, as recorded in our data.
Tenet Medicines was founded in 2023 and is based in Scotch Plains, United States. Focus is placed on the biotechnology sector, where therapeutics for autoimmune-driven inflammatory diseases are developed. The product pipeline includes TNT119, also known as budoprutug, an anti-CD19 monoclonal antibody designed to deplete B-cells. Indications addressed include systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. Operations center on advancing these treatments through clinical development.
Tenet Medicines has 1 investor. Key investors include Eliem Therapeutics.
Yes. Tenet Medicines was acquired by Eliem Therapeutics in April 2024.